Abstract
Glaucoma represents a major cause of vision loss throughout the world. Primary open-angle glaucoma, the most common form of glaucoma, is a chronic, progressive disease often, though not always, accompanied by elevated intraocular pressure (IOP). In this disorder, retinal ganglion cell loss and excavation of the optic nerve head produce characteristic peripheral visual field deficits. Patients with normal-tension glaucoma present with typical visual field and optic nerve head changes, without a documented history of elevated IOP. A variety of secondary causes, such as pigment dispersion syndrome and ocular trauma, can result in glaucoma as well. Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented.
Treatment options for glaucoma include medications, laser therapy and incisional surgery. Laser techniques for the reduction of IOP include argon laser trabeculoplasty and selective laser trabeculoplasty. Both techniques work by increasing outflow of aqueous humour through the trabecular meshwork. Surgical options for glaucoma treatment include trabeculectomy, glaucoma drainage tube implantation and ciliary body cyclodestruction. While each of these types of procedures is effective at lowering IOP, therapy usually begins with medications. Medications lower IOP either by reducing the production or by increasing the rate of outflow of aqueous humour within the eye.
Currently, there are five major classes of drugs used for the treatment of glaucoma: (i) cholinergics (acetylcholine receptor agonists); (ii) adrenoceptor agonists; (iii) carbonic anhydrase inhibitors (CAIs); (iv) β-adrenoceptor antagonists; and (v) prostaglandin analogues (PGAs). Treatment typically begins with the selection of an agent for IOP reduction. Although β-adrenoceptor antagonists are still commonly used by many clinicians, the PGAs are playing an increasingly important role in the first-line therapy of glaucoma. Adjunctive agents, such as α-adrenoceptor agonists and CAIs are often effective at providing additional reduction in IOP for patients not controlled on monotherapy. As with any chronic disease, effective treatment depends on minimising the adverse effects of therapy and maximising patient compliance. The introduction of a variety of well tolerated and potent medications over the past few years now allows the clinician to choose a treatment regimen on an individual patient basis and thereby treat this disorder more effectively.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995 Apr; 36(5): 774–86
Thylefors B, Negrel AD, Pararajasegaram R, et al. Global data on blindness. Bull World Health Organ 1995; 73: 115–21
Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 1991 Nov; 325(20): 1412–7
Rodriguez J, Sanchez R, Munoz B, et al. Causes of blindness and visual impairment in a population-based sample of US Hispanics. Ophthalmology 2002 Apr; 109(4): 737–43
Quigley HA, Vitale S. Models of glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997 Jan; 38(1): 83–91
American Academy of Ophthalmology preferred practice pattern for primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2003: 3
Drance SM, Sweeney VP, Morgan RW, et al. Studies of factors involved in the production of low tension glaucoma. Arch Ophthalmol 1973 Jun; 89(6): 457–65
Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994 Oct; 101(10): 1651–6
Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan: a nationwide glaucoma survey. Jpn J Ophthalmol 1991; 35(2): 133–55
Drance SM, Morgan RW, Sweeney VP. Shock-induced optic neuropathy: a cause of nonprogressive glaucoma. N Engl J Med 1973 Feb; 288(8): 392–8
Lewis RA, Hayreh SS, Phelps CD. Optic disk and visual field correlations in primary open-angle and low-tension glaucoma. Am J Ophthalmol 1983 Aug; 96(2): 148–5
Chumbley LC, Brubaker RF. Low-tension glaucoma. Am J Ophthalmol 1976 Jun; 81(6): 761–8
Caprioli J, Spaeth GL. Comparison of visual field defects in the low-tension glaucomas with those in the high-tension glaucomas. Am J Ophthalmol 1984 Jun; 97(6): 730–7
Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma: effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol 1980 Dec; 98(6): 2172–7
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 Jun; 120(6): 701–13
Campbell DG. Pigmentary dispersion and glaucoma: a new theory. Arch Ophthalmol 1979 Sep; 97(9): 1667–72
Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol 1966 Oct; 50(10): 570–86
Arkell SM, Lightman DA, Sommer A, et al. The prevalence of glaucoma among Eskimos of northwest Alaska. Arch Ophthalmol 1987 Apr; 105(4): 482–5
McLaren JW, Trocme SD, Relf S, et al. Rate of flow of aqueous humor determined from measurements of aqueous flare. Invest Ophthalmol Vis Sci 1990 Feb; 31(2): 339–46
Becker B. The decline in aqueous secretion and outflow facility with age. Am J Ophthalmol 1958 Nov; 46(5): 731–6
Hayashi M, Yablonski ME, Boxrud C, et al. Decreased formation of aqueous humour in insulin-dependent diabetic patients. Br J Ophthalmol 1989 Aug; 73(8): 621–3
Pederson JE. Ocular hypotony. Trans Ophthalmol Soc U K 1986; 105 (Pt 2): 220–6
Diestelhorst M, Krieglstein GK. The effect of the water-drinking test on aqueous humor dynamics in healthy volunteers. Graefes Arch Clin Exp Ophthalmol 1994 Mar; 232(3): 145–7
Reddy VN. Dynamics of transport systems in the eye. Invest Ophthalmol Vis Sci 1979 Oct; 18(10): 1000–18
Bill A. Blood circulation and fluid dynamics of the eye. Physiol Rev 1975 Jul; 55(3): 383–417
Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987 Mar; 28(3): 477–81
Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 2002; 47Suppl. 1: S2–5
Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002 Nov; 109(11): 1955–6
Diggory P, Franks W. Glaucoma: systemic side effects of topical medical therapy: a common and under recognized problem. J R Soc Med 1994 Oct; 87(10): 575–6
Whitson JT, Love R, Brown RH, et al. The effect of reduced eyedrop size and eyelid closure on the therapeutic index of phenylephrine. Am J Ophthalmol 1993 Mar; 115(3): 357–9
von Weber A. Die Ursache des Glaukoms. Albr Graefes Arch Ophthalmol 1877; 23: 91–4
Drance SM, Nash PA. The dose response of human intraocular pressure to pilocarpine. Can J Ophthalmol 1971 Jan; 6(1): 9–13
Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol 1987 Aug; 105(8): 1112–6
Barsam PC. Comparison of the effects of pilocarpine and echothiophate on intraocular pressure and outflow facility. Am J Ophthalmol 1972 May; 73(5): 742–9
Ellis PP, Esterdahl M. Echothiophate iodide therapy in children: effect upon blood Cholinesterase levels. Arch Ophthalmol 1967 May; 77(5): 598–601
Thoft RA. Incidence of lens changes in patients treated with echothiophate iodide. Arch Ophthalmol 1968 Sep; 80(3): 317–20
O’Brien CS, Swan KD. Carbaminoylcholinechloride in the treatment of glaucoma simplex. Arch Ophthalmol 1942 Feb; 27(2): 253–7
Reichert RW, Shields MB, Stewart WC. Intraocular pressure response to replacing pilocarpine with carbachol. Am J Ophthalmol 1988 Dec; 106(6): 747–8
Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980 Mar; 19(3): 256
Nagataki S, Brubaker RF. Early effect of epinephrine on aqueous formation in the normal human eye. Ophthalmology 1981 Mar; 88(3): 278–82
Becker B, Pettit TH, Gay AJ. Topical epinephrine therapy of open angle glaucoma. Arch Ophthalmol 1961 Aug; 66(2): 219–25
van Alphen GW. The adrenergic receptors of the intraocular muscles of the human eye. Invest Ophthalmol 1976 Jun; 15(6): 502–5
Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol 1968 May; 79(5): 552–62
Cashwell LF, Shields MB, Reed JW. Adrenochrome pigmentation. Arch Ophthalmol 1977 Mar; 95(3): 514–5
McCarthy RW, LeBlanc R. A ‘black cornea’ secondary to topical epinephrine. Can J Ophthalmol 1976 Oct; 11(4): 336–40
Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology 1978 Mar; 85(3): 268–75
Kass MA, Mandell AI, Goldberg I, et al. Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study. Arch Ophthalmol 1979 Oct; 97(10): 1865–6
Lee DA, Topper JE, Brubaker RF. Effect of Clonidine on aqueous humor flow in normal human eyes. Exp Eye Res 1984 Mar; 38(3): 239–46
Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995 Mar; 102(3): 456–61
Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 1988 Jul; 106(7): 912–5
Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995 Mar; 113(3): 293–6
Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995 Dec; 113(12): 1514–7
Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41Suppl. 1: S27–37
Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997 Jul; 115(7): 847–52
Serie JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure: the Brimonidine Study Group III. Surv Ophthalmol 1996 Nov; 41Suppl. 1: S39–47
Wilkerson M, Lewis RA, Shields MB. Follicular conjunctivitis associated with apraclonidine. Am J Ophthalmol 1991 Jan; 111(1): 105–6
Stewart WC, Ritch R, Shin DH, et al. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Arch Ophthalmol 1995 Mar; 113(3): 287–92
Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs. 0.5% timolol (Apraclonidine Primary Therapy Study Group). Arch Ophthalmol 1996 Aug; 114(8): 938–42
Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002 Apr; 11(2): 119–26
Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor (Diamox). Am J Ophthalmol 1954 Jan; 37(1): 13–7
Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982 Feb; 93(2): 232–7
Fraunfelder FT, Meyer SM, Bagby Jr GC, et al. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985 Jul; 100(1): 79–81
Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995 Aug; 113(8): 1009–16
Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998 Oct; 105(10): 1945–51
Kimal AM, Topalkara A, Guier C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol 1998 Jan; 22(1): 37–42
Stewart WC, Sharpe ED, Harbin TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000 Jun; 129(6): 723–7
Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004 Apr; 13(2): 168–73
Silver LH. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 2000 Jan; 44Suppl. 2: S155–62
Barnebey H, Kwok SY. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000 Oct; 22(10): 1204–12
Sugrue MF, Mallorga P, Schwam H, et al. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 1990 Jun; 9(6): 607–15
Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999 Apr; 127(4): 403–6
Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998 Sep; 126(3): 400–8
Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978 Nov; 96(11): 2045–8
Steinen RF, Thomas JV, Boger III WP. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981 Jan; 99(1): 100–3
Kobelt G, Jonsson L, Gerdtham U, et al. Direct costs of glaucoma management following initiation of medical therapy: a simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998 Nov; 236(11): 811–21
Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci 1985 Oct; 26(10): 1315–9
Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977 Apr; 95(4): 601–4
Wilson RP, Kanal N, Spaeth GL. Timolol: its effectiveness in different types of glaucoma. Ophthalmology 1979 Jan; 86(1): 43–50
Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol 1979 May; 23(6): 395–8
Shedden A, Laurence J, Tipping R, et al. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution in adults with primary open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther 2001 Mar; 23(3): 440–50
Stewart WC, Sharpe ED, Stuart JA, et al. The safety and efficacy of timolol 0.5% in xanthum gum versus timolol gel forming solution 0.5%. Curr Eye Res 2002 May 24(5): 387–391
Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol (0.5%) therapy: a cross-over study. Ophthalmology 1992 Dec; 99(3): 424–9
Boozman FW, Carriker R, Foerster R, et al. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure. Arch Ophthalmol 1988 May; 106(5): 614–8
Geyer O, Lazar M, Novack GD, et al. Levobunolol compared with timolol: a four-year study. Br J Ophthalmol 1988 Dec; 72(12): 892–6
Scoville B, Mueller B, White BG, et al. A double-masked comparison of Carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988 Feb; 105(2): 150–4
Stewart WC, Shields MB, Allen RC, et al. A 3-month comparison of 1% and 2% Carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1991 Mar; 229(3): 258–61
Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular Carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993 Nov; 116(5): 600–11
Serie JB, Lustgarten JS, Podos SM. A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. Am J Ophthalmol 1991 Sep; 112(3): 302–7
Muller O, Knobel HR. Effectiveness and tolerance of metipranolol: results of a multi-center long-term study in Switzerland. Klin Monatsbl Augenheilkd 1986 Jan; 188(1): 62–3
Krieglstein GK, Novack GD, Voepel E, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br J Ophthalmol 1987 Apr; 71(4): 250–3
Coakes RL, Mackie IA, Seal DV. Effects of long-term treatment with timolol on lacrimal gland function. Br J Ophthalmol 1981 Sep; 65(9): 603–5
Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 1991 Sep; 75(9): 5519–23
Melles RB, Wong IG. Metipranolol-associated granulomatous iritis. Am J Ophthalmol 1994 Dec; 118(6): 712–5
McMahon CD, Shaffer RN, Hoskins HDJ, et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979 Oct; 88(4): 736–8
Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980 May; 87(5): 447–50
Velde TM, Kaiser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. Arch Intern Med 1983 Aug; 143(8): 1627
Coppeto JR. Timolol-associated myasthenia gravis. Am J Ophthalmol 1984 Aug; 98(2): 244–5
Fraunfelder FT. Interim report: national registry of possible drug-induced ocular side effects. Ophthalmology 1980 Feb; 87(2): 87–90
Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology 1983 Nov; 90(11): 1369–72
Caldwell Dr, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol 1984 Apr; 102(4): 539–40
Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a beta 1-adrenergic antagonist. Am J Ophthalmol 1985 Dec; 100(6): 777–82
Collignon-Brach J. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr Eye Res 1992 Jan; 11(1): 1–3
Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991 Dec; 112(6): 678–1
Hoste AM, Sys SU. The relaxant action of betaxolol on isolated bovine retinal microarteries. Curr Eye Res 1994 Jul; 13(7): 483–7
Hoste AM. Ca2+ channel blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J Cardiovasc Pharmacol 1998 Sep; 32(3): 390–6
Schoene RB, Sharpe ED, Harbin TS, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984 Jan; 97(1): 86–92
Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol 1986 Aug; 102(2): 274–5
Roholt PC. Betaxolol and restrictive airway disease: case report. Arch Ophthalmol 1987 Sep; 105(9): 1172
Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, Sept 1985–Sept 1986 [letter]. Am J Ophthalmol 1987 Apr; 103(4): 592
Ball S. Congestive heart failure from betaxolol: case report. Arch Ophthalmol 1987 Mar; 105(3): 320
Lynch MG, Whitson JT, Brown RH, et al. Topical beta-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol. Arch Ophthalmol 1988 Jul; 106(7): 908–11
Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in IOP are an independent risk factor in patients with glaucoma. J Glaucoma 2000 Apr; 9(2): 134–42
Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999 May; 106(5): 997–1004
Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997 Feb; 41Suppl. 2: S139–44
Hylton C, Robin AL. Update on prostaglandin analogues. Curr Opin Ophthalmol 2003 Apr; 14(2): 65–9
Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993 Oct; 111(1): 1351–8
Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003 May; 135(5): 688–703
Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996 Jan; 103(1): 138–47
Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996 Jan; 103(1): 126–37
Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study. Arch Ophthalmol 1996 Aug; 114(8): 929–32
Orzatesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000 Aug; 41(9): 2566–73
O’Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3-month randomized study. Ireland Latanoprost Study Group. Br J Ophthalmol 2000 Jun; 84(6): 579–82
Dubiner HB, Mroz M, Shapiro AM, et al. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001 Dec; 23(12): 1969–83
Data on file, Pfizer Ophthalmics Inc., New York, 2003
Morgan PV, Proniuk S, Blanchard J, et al. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma 2001 Oct; 10(5): 401–5
Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocular Pharmacol Ther 2001 Oct; 17(5): 421–32
Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001 Oct; 132(4): 472–84
Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP: a six-month, masked, multicenter trial. Ophthalmology 2002 May; 109(5): 998–1008
Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2002 Oct; 10(5): 414–22
Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001 Dec; 132(6): 860–8
Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004 Jan; 26(1): 84–91
Whitson JT. Travoprost-a new prostaglandin analogue for the treatment of glaucoma. Expert Opin Pharmacother 2002 Jul; 3(7): 965–77
Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003 May; 305(2): 772–85
Hellberg MR, Ke TL, Haggard K, et al. The hydrolysis of the prostaglandin analogue prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J Ocul Pharmacol Ther 2003 Apr; 19(2): 97–103
Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 2001 May; 45(4): S347–51
Sherwood M, Brandt J. Six-month comparison of bimatoprost q.d. and b.i.d. with timolol b.i.d. in patients with elevated intraocular pressure. Surv Ophthalmol 2001 May; 45(4): S361–8
Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001 May–Jun; 18(3): 110–21
Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003 Jan; 135(1): 55–63
Coleman AL, Lerner F, Bernstein P, et al. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003 Dec; 110(12): 2362–8
Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998 Oct; 105(10): 1936–44
Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother 2002 Dec; 3(12): 1753–62
Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including Pseudoexfoliation glaucoma or ocular hypertension: 6-month data. Am J Ophthalmol 2002 Jan; 133(1): 1–10
Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002 Dec; 134(6): 863–71
Hommer A, Kapik B, Shams N. Unoprostone as adjunctive therapy to timolol: a double masked randomized study versus brimonidine and dorzolamide. Br J Ophthalmol 2003 May; 87(5): 592–8
Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997 Feb; 41Suppl. 2: S111–5
Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997 Feb; 41Suppl. 2: S129–38
Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998 Jul; 126(1): 37–41
Dios Castro E, Maquet Dusart JA. Latanoprost-associated recurrent herpes simplex keratitis. Arch Soc Esp Oftalmol 2000 Nov; 75(11): 775–8
Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and Pseudophakic eyes. Am J Ophthalmol 1998 Oct; 126(4): 602–4
Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998 Jul; 126(1): 134–5
Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999 Feb; 8(1): 24–30
Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy. Arch Ophthalmol 2002 Jul; 120(7): 915–22
Netland PA, Michael M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2003 Jan–Feb; 20(1): 20–30
Chiselita D, Apatachioae I, Poiata I. The ocular hypotensive effect of the combination of latanoprost and dorzolamide. Oftalmologia 1999 Jan; 46(1): 39–45
O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002 Jun; 133(6): 836–7
Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timololcombination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003 Mar; 110(3): 615–24
Orzatesi N, Rossetti L, Bottali A, et al. The effect of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003 Apr; 121(4): 453–7
Airaksinen PJ, Valkonen R, Stenborg T, et al. A double-masked study of timolol and pilocarpine combined. Am J Ophthalmol 1987 Dec; 104(6): 587–90
Scharrer A, Ober M. Metipranolol 0.1% and pilocarpine 2% as a fixed combination compared to each substance alone in the treatment of glaucoma: a controlled, randomized clinical study comparing the intraindividual effects and tolerance. Klin Monatsbl Augenheilkd 1986 Dec; 189(6): 450–5
Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma: a pilot study. Arch Ophthalmol 1979 Feb; 97(2): 319–22
Babizhayev MA, Brodskaya MW, Mamedov NG, et al. Clinical, structural and molecular phototherapy effects of laser irradiation on the trabecular meshwork of human glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol 1990 Jan; 228(1): 90–100
Wise JB. Long-term control of adult open angle glaucoma by argon laser treatment. Ophthalmology 1981 Mar; 88(3): 197–202
Wilensky JT, Jampol LM. Laser therapy for open angle glaucoma. Ophthalmology 1981 Mar; 88(3): 213–7
Tuulonen A, Niva AK, Alanko HI. A controlled five-year follow-up study of laser trabeculoplasty as primary therapy for open-angle glaucoma. Am J Ophthalmol 1987 Oct; 104(4): 334–8
Frucht J, Bishara S, Ticho U. Early intraocular pressure response following laser trabeculoplasty. Br J Ophthalmol 1985 Oct; 69(10): 771–3
Thomas JV, Simmons RJ, Belcher III CD. Argon laser trabeculoplasty in the presurgical glaucoma patient. Ophthalmology 1982 Mar; 89(3): 187–97
Hoskins Jr HD, Hetherington Jr J, Minckler DS, et al. Complications of laser trabeculoplasty. Ophthalmology 1983 Jul; 90(7): 796–9
Latina MA, Sibayan SA, Shin DH, et al. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 1998 Nov; 105(11): 2082–8
Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001 Apr; 108(4): 773–9
Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty vs argon laser trabeculoplasty: a prospective randomized clinical trial. Br J Ophthalmol 1999 Jun; 83(6): 718–22
Cairns JE. Trabeculectomy: preliminary report of a new method. Am J Ophthalmol 1968 Oct; 66(4): 673–9
Ruderman JM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol 1987 Sep; 104(3): 218–24
Palmer SS. Mitomycin as an adjunct chemotherapy with trabeculectomy. Ophthalmology 1991 Mar; 98(3): 317–21
Zimmerman TJ, Kooner KS, Ford VJ, et al. Effectiveness of nonpenetrating trabeculectomy in aphakic patients with glaucoma. Ophthalmic Surg 1984 Jan; 15(1): 44–50
Chiselita D. Non-penetrating deep sclerectomy versus trabeculectomy in primary open angle glaucoma surgery. Eye 2001 Apr; 15 (Pt 2): 197–201
Whitson JT. Recent developments in glaucoma drainage implant surgery. Int Ophthalmol Clin 1999 Summer; 39(3): 43–55
deRoetth Jr A. Cryosurgery for the treatment of advanced chronic simple glaucoma. Am J Ophthalmol 1966 Mar; 61(3): 443–50
Albaugh CH, Dunphy EB. Cyclodiathermy. Arch Ophthalmol 1942 Mar; 27(3): 543–57
Peyman GA, Naguib KS, Gaasterland D. Transscleral application of a semiconductor diode laser. Lasers Surg Med 1990; 10(6): 569–75
Acknowledgements
Supported in part by an unrestricted research grant from Research to Prevent Blindness, Inc., New York, NY, USA.
The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marquis, R.E., Whitson, J.T. Management of Glaucoma: Focus on Pharmacological Therapy. Drugs Aging 22, 1–21 (2005). https://doi.org/10.2165/00002512-200522010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200522010-00001